hs-CRP: making sense of inflammation and cardiovascular risk

Editorial draft. The text has been read in full and copyedited. Clinical review and source verification are still pending.

What hs-CRP measures

CRP is a protein the liver makes in response to immune activation. The name hs-CRP refers to measuring it with a high-sensitivity method. When tissue is stressed or damaged, immune messengers (mainly interleukin-6) signal the liver to release CRP into the bloodstream. The high-sensitivity assay detects very low concentrations, which makes it suitable for spotting small, chronic elevations that matter for cardiovascular and metabolic risk, not just the large spikes seen in acute infections.

What hs-CRP reflects about systemic inflammation

The half-life of CRP is short and constant: about 19 hours. Because the rate of breakdown is largely constant, the concentration in the blood depends mainly on the rate of production, which in turn reflects the intensity of the upstream inflammatory signals. That makes hs-CRP a sensitive indicator of immune system activity rather than of kidney function or fluid shifts.

hs-CRP reflects the intensity of inflammatory signals but does not identify their source: it rises with infections, autoimmune flares, visceral fat, sleep apnea and recovery processes after exercise. A single raised result needs context and repeat testing. At values above 10 mg/L, an acute process is the more likely explanation; before assessing cardiovascular risk, the value should be measured again after recovery.

The high-sensitivity assay is calibrated for the range of 0.1–10 mg/L, which is relevant to vascular biology. Standard CRP is geared toward much higher values. The two are not interchangeable, and comparing results from different test types can be misleading.

In the JUPITER trial, people with normal LDL but raised hs-CRP who took statins had fewer cardiovascular events, which supports a role for inflammatory activity in prevention strategies. Mendelian randomization studies suggest that CRP itself may be more of a signal than a cause (upstream immune pathways probably cause the damage), but the marker still carries prognostic value. Source

How hs-CRP values are classified

The American Heart Association describes three cardiovascular risk tiers: below 1 mg/L (lower risk), 1–3 mg/L (average risk) and above 3 mg/L (higher risk). Values above 10 mg/L point to an acute process rather than chronic cardiovascular risk and should be retested after recovery. These categories are population-level guides, not diagnoses. In women, older adults and people on estrogen therapy or during pregnancy, values are often higher because of signaling effects in the liver. Assay calibration can also vary slightly between labs.

What raised values can mean

A raised hs-CRP is common and nonspecific. A recent illness, an injury, dental treatment, a vaccination or intense exercise can each push hs-CRP up for days. Chronic causes include visceral obesity, periodontitis, sleep apnea, autoimmune diseases, chronic kidney disease, smoking and estrogen-containing medicines. If hs-CRP is mildly raised and stays that way on repeat testing, doctors look at the related markers and risk factors together. In cardiovascular prevention, a persistently raised hs-CRP counts as a risk-enhancing factor when the 10-year ASCVD risk is borderline or intermediate. It does not indicate disease, but it suggests that inflammatory activity may need more attention in the prevention plan.

What low values can mean

A very low hs-CRP is common in healthy, well-rested people; many active adults are below 1 mg/L when sleep, diet and metabolic health are in good shape. In rare cases, a blunted CRP response can occur with severe liver dysfunction or marked immunosuppression, but that would fit into a broader clinical picture. A consistently low, stable value in an otherwise healthy person generally reflects a lower inflammatory burden.

What can raise hs-CRP temporarily or long term

Several factors determine the hs-CRP value at the moment blood is drawn.

Acute temporary triggers (illness, injury, vaccination, dental procedures and intense physical activity) can raise hs-CRP for 24–72 hours or longer. These spikes are expected and do not reflect the chronic inflammatory burden. For a risk assessment, blood should be drawn under stable conditions: not during a cold, not within 48 hours of intense physical exertion, and not right after a vaccination. To assess cardiovascular risk, two draws at least two weeks apart are standard, to account for these temporary rises.

Visceral obesity is one of the most common chronic causes. Fat tissue, especially around the belly, releases inflammatory cytokines that keep hs-CRP raised over time. Reducing fat mass, by whatever means, tends to bring a corresponding drop in hs-CRP.

Sleep and circadian disruption increase sympathetic tone and inflammatory mediators. Sleep that is too short or irregular is associated with higher hs-CRP; regular sleep times are associated with lower baseline immune activation.

With exercise, short-term and long-term effects differ. Acute, intense training sessions can briefly drive hs-CRP up while muscle repair is under way. Consistent training over time can lower the baseline by improving insulin sensitivity, reducing visceral fat and increasing anti-inflammatory myokines from muscle.

Metabolic factors (insulin resistance, raised fasting glucose and poor blood sugar control) affect inflammatory activity. Treating a metabolic disorder often lowers hs-CRP along with the glycemic markers.

Medicines and therapies have direct effects. Statins lower hs-CRP beyond their LDL-lowering effect. Estrogen therapies raise it through signaling in the liver. Glucocorticoids and cytokine-targeted biologics can lower the value. These effects are independent of lifestyle and should be taken into account when interpreting results.

Diet plays a part too. Low vitamin D status, low magnesium intake and low intake of marine omega-3 fatty acids each correlate with higher inflammatory markers in observational data, and some intervention studies have seen modest reductions. There is some evidence that curcumin lowers CRP in certain contexts, although product quality and dosing vary. A diet high in ultra-processed foods, too much added sugar and frequent drinking can drive inflammatory signals up.

Other chronic conditions (periodontitis, sleep apnea, autoimmune flares and chronic kidney disease) raise hs-CRP regardless of lifestyle factors and need clinical treatment.

Which lab values can complement hs-CRP

• ApoB: ApoB counts atherogenic particles directly. Raised ApoB together with raised hs-CRP points to a higher burden of atherogenic particles alongside inflammatory activity, a combination that carries more risk than either marker alone.

• Ferritin: Ferritin is also an acute-phase reactant. A rise alongside hs-CRP can stem from active inflammation or from iron overload linked to liver stress. Looking at both values together helps answer whether a high ferritin is caused by inflammation or by an iron load.

• ESR (BSG in German): the erythrocyte sedimentation rate reflects shifts in plasma proteins over hours to days. When ESR and hs-CRP are both raised, that confirms systemic inflammation. They can diverge: hs-CRP rises faster in the early acute phase, while ESR can stay raised in chronic conditions after hs-CRP has normalized.

• Albumin: Albumin is a negative acute-phase reactant. It falls as hs-CRP rises during substantial inflammation. A low albumin level combined with a raised hs-CRP points to a high inflammatory burden that is impairing synthesis in the liver.

• Fasting glucose: Raised fasting glucose together with raised hs-CRP links metabolic dysfunction with inflammatory activity. Treating the underlying metabolic disorder often lowers both markers at once.

When should hs-CRP be retested to see a real trend?

The roughly 19-hour half-life of hs-CRP means that the production rate, not clearance, sets the level, and values can change within days of a meaningful change in inflammatory burden. This responsiveness is useful for monitoring, but it also means a single reading can easily be skewed by temporary events.

To assess cardiovascular risk, the AHA recommends two draws at least two weeks apart, to account for temporary rises from illness or physical activity. Both blood draws should take place under stable conditions, without acute illness and not within 48 hours of intense physical exertion.

To monitor chronic inflammatory trends, remeasuring every 4 to 8 weeks after a meaningful lifestyle change or clinical illness is a sensible interval, because the underlying factors (visceral fat, sleep, metabolic health) change over weeks to months.

For comparisons, use the same lab and the same test type. High-sensitivity (hs-CRP) and standard CRP assays are not interchangeable. If a result exceeds 10 mg/L, it likely points to an acute process; remeasuring after full recovery makes the risk assessment easier.

When a raised hs-CRP should be checked by a doctor

Urgency depends on symptoms and clinical context, not on hs-CRP alone. To check a temporary rise, the original material suggests a repeat measurement under stable conditions, at least two weeks after an acute illness, a vaccination or a period of intense training. Persistently raised values should be assessed by a doctor.

Situations that call for a clinical conversation include: hs-CRP consistently above 3 mg/L with no obvious temporary explanation; values above 10 mg/L that persist after recovery from an acute illness; or any rise that comes with borderline cardiovascular risk, unexplained metabolic changes or symptoms that other tests have not explained. In these situations, hs-CRP can act as a risk-enhancing factor that changes prevention decisions, whether on lipid management, metabolic interventions or further diagnostic workup.

Measuring hs-CRP is quick and inexpensive, and its value grows when the trend is followed over time together with related markers. Combined with ApoB, fasting glucose, ferritin and albumin, it helps bring lipid burden, metabolic burden and inflammatory activity together, giving an overall picture of cardiovascular and metabolic health that goes beyond a single number.

Frequently asked questions

What is hs-CRP and what does it measure?

High-sensitivity CRP testing (hs-CRP) measures a blood marker that reflects low-grade systemic inflammation. Compared with the standard method, the hs-CRP test is sensitive enough to detect subtle inflammatory signals linked to metabolic and cardiovascular risk. The CRP being measured is produced in the liver in response to cytokines such as IL-6.

What is a normal hs-CRP value?

The American Heart Association categorizes cardiovascular risk from hs-CRP as follows: low risk below 1.0 mg/L, average risk 1.0–3.0 mg/L and high risk above 3.0 mg/L. Values above 10 mg/L typically point to an acute infection or inflammation rather than chronic risk and should be assessed clinically before any cardiovascular risk evaluation.

What causes raised hs-CRP?

Chronic low-grade inflammation from visceral fat, insulin resistance, poor sleep, physical inactivity, smoking, periodontitis and a suboptimal diet are among the most common causes of persistently raised hs-CRP. Short-term rises can also come from illness, injury, intense physical activity or hormonal fluctuations.

Can a high hs-CRP cause symptoms?

Mild hs-CRP rises in the cardiovascular risk range (1–3 mg/L) are typically symptom-free. Stronger chronic inflammation can show up as fatigue, joint stiffness or trouble concentrating, but these symptoms are nonspecific. hs-CRP can also signal inflammatory activity without any obvious complaints. Whether a measurement for risk assessment makes sense depends on your individual situation.

How can I lower my hs-CRP?

Lifestyle factors consistently linked to lower hs-CRP include regular endurance training, a diet rich in vegetables and omega-3 fatty acids and low in ultra-processed foods, enough sleep (7–9 hours), quitting smoking and maintaining a healthy body weight. Omega-3 fatty acids and certain anti-inflammatory dietary patterns have lowered hs-CRP in controlled studies. A medical assessment helps narrow down possible causes of your individual pattern.

Is hs-CRP a useful marker for heart disease risk?

Yes. The JUPITER trial, published in the New England Journal of Medicine in 2008, showed that raised hs-CRP was an independent predictor of cardiovascular events even in people with normal LDL cholesterol. hs-CRP is now included in several cardiovascular risk calculators as an additional marker, which is especially useful when the usual blood lipid values suggest borderline risk.

How often should hs-CRP be tested?

To assess cardiovascular risk, hs-CRP is best interpreted from two separate measurements at least two weeks apart, to account for temporary rises from illness or physical activity. The original material suggests routine checks every 6–12 months; that does not establish a general indication for most adults. More frequent testing (every 4–8 weeks) can be useful when actively adjusting diet, exercise or other inflammation-related variables.

Does intense training temporarily raise hs-CRP?

Yes. Acute, intense training can temporarily raise CRP for 24–72 hours afterward because of muscle repair processes. This is a normal physiological response, not a sign of pathological inflammation. For a follow-up measurement that is as unaffected as possible, the original material recommends avoiding intense physical exertion in the 48 hours before the blood draw.

Sources

• Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC, Jr., Taubert K, Tracy RP, Vinicor F, Centers for Disease Control and Prevention, American Heart Association (2003). Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107(3), 499-511. https://doi.org/10.1161/01.cir.0000052939.59093.45 Source

• Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England journal of medicine, 359(21), 2195-207. https://doi.org/10.1056/NEJMoa0807646 Source

• C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC), Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T, Engert JC, Clarke R, Davey-Smith G, Nordestgaard BG, Saleheen D, Samani NJ, Sandhu M, Anand S, Pepys MB, Smeeth L, Whittaker J, Casas JP, … Danesh J (2011). Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ, 342, d548. https://doi.org/10.1136/bmj.d548 Source

• Grundy SM, Stone NJ, Guideline Writing Committee for the 2018 Cholesterol Guidelines (2019). 2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline. Annals of internal medicine, 170(11), 779-783. https://doi.org/10.7326/M19-0365 Source

• Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J (2010). C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet, 375(9709), 132-40. https://doi.org/10.1016/S0140-6736(09)61717-7 Source